These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 9536083)

  • 21. An evaluation of common breast cancer gene mutations in a population of Ashkenazi Jews.
    Lalloo F; Cochrane S; Bulman B; Varley J; Elles R; Howell A; Evans DG
    J Med Genet; 1998 Jan; 35(1):10-2. PubMed ID: 9475087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors.
    Gotlieb WH; Friedman E; Bar-Sade RB; Kruglikova A; Hirsh-Yechezkel G; Modan B; Inbar M; Davidson B; Kopolovic J; Novikov I; Ben-Baruch G
    J Natl Cancer Inst; 1998 Jul; 90(13):995-1000. PubMed ID: 9665148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.
    Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ
    Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age at diagnosis of cancer in 185delAG BRCA1 mutation carriers of diverse ethnicities: tentative evidence for modifier factors.
    Laitman Y; Michaelson-Cohen R; Chen-Shtoyerman R; Goldberg Y; Reish O; Bernstein-Molho R; Levy-Lahad E; Baruch NEB; Kedar I; Evans DG; Haim S; Paluch-Shimon S; Friedman E
    Fam Cancer; 2021 Jul; 20(3):189-194. PubMed ID: 33165727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer.
    Foulkes WD; Wong N; Brunet JS; Bégin LR; Zhang JC; Martinez JJ; Rozen F; Tonin PN; Narod SA; Karp SE; Pollak MN
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2465-9. PubMed ID: 9815648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
    Struewing JP; Hartge P; Wacholder S; Baker SM; Berlin M; McAdams M; Timmerman MM; Brody LC; Tucker MA
    N Engl J Med; 1997 May; 336(20):1401-8. PubMed ID: 9145676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of the 185delAG BRCA1 mutation in a Spanish Gypsy population.
    Díez O; Doménech M; Alonso MC; Brunet J; Sanz J; Cortés J; del Río E; Baiget M
    Hum Genet; 1998 Dec; 103(6):707-8. PubMed ID: 9921907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRCA1 185delAG mutation in a non-Ashkenazi Jewish woman with early-onset breast and ovarian cancer.
    Menczer J; Theodor L; Friedman E
    Am J Obstet Gynecol; 1997 Mar; 176(3):731. PubMed ID: 9077645
    [No Abstract]   [Full Text] [Related]  

  • 30. Prevalence of BRCA1 and BRCA2 Jewish mutations in Spanish breast cancer patients.
    Díez O; Osorio A; Robledo M; Barroso A; Domènech M; Cortés J; Albertos J; Sanz J; Brunet J; SanRomán JM; Alonso MC; Baiget M; Benítez J
    Br J Cancer; 1999 Mar; 79(7-8):1302-3. PubMed ID: 10098775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haplotype analysis of a BRCA1: 185delAG mutation in a Chilean family supports its Ashkenazi origins.
    Ah Mew N; Hamel N; Galvez M; Al-Saffar M; Foulkes WD
    Clin Genet; 2002 Aug; 62(2):151-6. PubMed ID: 12220453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.
    Finkelman BS; Rubinstein WS; Friedman S; Friebel TM; Dubitsky S; Schonberger NS; Shoretz R; Singer CF; Blum JL; Tung N; Olopade OI; Weitzel JN; Lynch HT; Snyder C; Garber JE; Schildkraut J; Daly MB; Isaacs C; Pichert G; Neuhausen SL; Couch FJ; van't Veer L; Eeles R; Bancroft E; Evans DG; Ganz PA; Tomlinson GE; Narod SA; Matloff E; Domchek S; Rebbeck TR
    J Clin Oncol; 2012 Apr; 30(12):1321-8. PubMed ID: 22430266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers.
    Gal I; Gershoni Baruch R; Haber D; Dagan E; Eisenberg-Barzilai S; Zidan J; Friedman E
    Fam Cancer; 2004; 3(1):11-4. PubMed ID: 15131400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer.
    Gershoni-Baruch R; Dagan E; Fried G; Bruchim Bar-Sade R; Sverdlov-Shiri R; Zelicksson G; Friedman E
    Eur J Cancer; 2000 May; 36(8):983-6. PubMed ID: 10885601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado.
    Mullineaux LG; Castellano TM; Shaw J; Axell L; Wood ME; Diab S; Klein C; Sitarik M; Deffenbaugh AM; Graw SL
    Cancer; 2003 Aug; 98(3):597-602. PubMed ID: 12879478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
    Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
    Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The I1307K APC polymorphism: prevalence in non-Ashkenazi Jews and evidence for a founder effect.
    Shtoyerman-Chen R; Friedman E; Figer A; Carmel M; Patael Y; Rath P; Fidder HH; Bar-Meir S; Theodor L
    Genet Test; 2001; 5(2):141-6. PubMed ID: 11551102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
    Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE
    Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
    Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
    Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
    Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.